

P R E S S R E L E A S E

SHS acquires Spiegelberg

Tübingen, Hamburg, August 4, 2011 – SHS Gesellschaft für Beteiligungsmanagement mbH (SHS), a growth investor in Tübingen, has acquired the corporate shares in Spiegelberg (GmbH & Co.) KG (Spiegelberg). SHS and Spiegelberg announced this today. Spiegelberg, a Hamburg-based medical technologies company, develops, produces and sells highly specialized catheters and probes for neurosurgical use in the brain as well as antimicrobial products to prevent hospital acquired infections.

Spiegelberg was founded by Dr. Andreas Spiegelberg in 1986 and has since become a renowned specialist in the monitoring of intracranial pressure as well as external ventricular drainage (EVD). With its antimicrobial Silverline® products, Spiegelberg offers an especially promising technology for the future. The fungicidal and bactericidal silver coating on these products plays a major role in preventing hospital acquired infections. Spiegelberg generated sales of 2.5 million euros in 2010, and this number is likely to rise to 3 million euros in 2011. The company has 30 employees.

The price is being paid over an extended period of time, which means that the sellers of the Spiegelberg holdings will still receive a share of the company's profits. SHS has acquired the shares together with Join & Venture GmbH, established by medical technology entrepreneurs Dr. Heinz Fischer and Frank Sodha. The parties agreed to keep the price confidential. Dr. Andreas Spiegelberg will continue to be managing director of Spiegelberg (GmbH & Co.) KG together with Frank Sodha who will also become managing director.

“We are delighted to have found SHS, an investor with so much expertise and experience in the area of medical technologies. This move will provide us with the new resources, synergies and sales potential we need to continue our profitable growth,” said Dr. Andreas Spiegelberg, founder and managing director of Spiegelberg (GmbH & Co.) KG.

“Spiegelberg is a renowned medical technology specialist in the fields of intracranial pressure monitoring as well as antibacterial technologies. The company will represent yet another profitable, innovative firm in our portfolio. We are proud to play an active role in Spiegelberg’s future growth,” explained Dr. Bernhard Schirmers, founder and partner of SHS Gesellschaft für Beteiligungsmanagement mbH.

About SHS Gesellschaft für Beteiligungsmanagement mbH

SHS Gesellschaft für Beteiligungsmanagement, founded in Tübingen in 1993, offers finance and advice for innovative companies in new industries, especially in the healthcare and life sciences sectors. With their current investment funds, SHS holds around 120 million euro of investment capital. The chief partners are the former McKinsey consultants Bernhard Schirmers and Reinhilde Spatscheck, and Hubertus Leonhardt, former Corporate Finance Project Leader at Arthur Andersen.

Investors have provided around 50 million euro for the current SHS III Fund. Investors include the European Investment Fund (EIF), through which the SHS Fund receives funding from the ERP-EIF fund of funds and from the ‘Competitiveness and Innovation Framework Programme’ (CIP) of the European Union; the KfW Bankengruppe, a pension fund, Fund of Funds as well as various businesspersons, family offices, and the SHS management team itself.

SHS has already used this latest fund to invest in several fast-growing technology companies in 2010 and 2011. Further investments are planned.

About Spiegelberg (GmbH & Co.) KG

Spiegelberg (GmbH & Co.) KG is an innovative medical technologies company based in Hamburg. The company develops, produces and sells highly specialized catheters and probes for neurosurgical use in the brain

as well as antimicrobial products to prevent hospital acquired infections. It was founded by Dr. Andreas Spiegelberg in 1986.

Spiegelberg (GmbH & Co.) KG is widely recognized as a specialized provider of products for monitoring intracranial pressure (ICP) and external ventricular drainage (EVD). With its antimicrobial Silverline® products, Spiegelberg offers an especially promising technology for the future. The fungicidal and bactericidal silver coating on these products plays a major role in preventing hospital acquired infections.

For more information:

Ira Wülfing

IRA WÜLFING KOMMUNIKATION GmbH

t: +49.(0)89. 2000 30-33

f: +49.(0)89. 2000 30-40

ira@wuelfing-kommunikation.de